In respect of relapse, a study on younger MCL patients showing 11% of mutation frequency and 26.9% of mean allele frequency for TP53 mutations demonstrated the independent prognostic impact of TP53 mutations on time to relapse47. The gene discussed is TP53; the disease is mantle cell lymphoma.